Travis Monchamp, MD
Endocrinology, Diabetes & Metabolism · Bend, ORNPI 1396776324
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 350 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations.
Across 350 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$764
- Novo Nordisk$732
- Abbott$643
- AstraZeneca$583
- Lilly USA, LLC$564
- Dexcom, Inc.$359
- plus $3K from 34 others
Across 19 payments — averaging $5543.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$88K
- Eli Lilly$17K
What the payments were for
- Food & beverage$6,70599%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 36 | $764 |
| Novo Nordisk | 40 | $732 |
| Abbott | 36 | $643 |
| AstraZeneca(2 entities) | 29 | $583 |
| Lilly USA, LLC | 31 | $564 |
| Dexcom, Inc. | 18 | $359 |
| Tandem Diabetes Care, Inc. | 16 | $333 |
| Mannkind Corporation | 13 | $301 |
| AbbVie | 12 | $211 |
| Bayer | 9 | $189 |
| Sanofi-aventis U.S. LLC | 10 | $179 |
| Medtronic(2 entities) | 10 | $168 |
| Merck | 8 | $143 |
| Amarin Pharma, Inc. | 7 | $140 |
| Novartis | 7 | $127 |
| Corcept Therapeutics | 5 | $117 |
| IBSA Pharma Inc. | 6 | $116 |
| Vistapharm, Inc. | 5 | $99 |
| Recordati_rare_diseases_inc. | 4 | $92 |
| Antares Pharma, Inc. | 4 | $75 |
| Kowa Pharmaceuticals America, Inc. | 5 | $73 |
| Neurocrine Biosciences, Inc. | 3 | $72 |
| Esperion Therapeutics, Inc. | 4 | $70 |
| Pfizer | 3 | $58 |
| Boehringer Ingelheim | 3 | $56 |
| Amryt Pharma Holdings Ltd | 2 | $55 |
| Ultragenyx Pharmaceutical Inc. | 3 | $50 |
| Insulet Corporation | 2 | $48 |
| Xeris Pharmaceuticals, Inc. | 2 | $45 |
| Ascendis Pharma Endocrinology Inc | 3 | $44 |
| BETA Bionics, Inc. | 2 | $43 |
| Radius Health, Inc. | 2 | $39 |
| Johnson & Johnson | 2 | $36 |
| Senseonics, Incorporated | 2 | $29 |
| Ferring Pharmaceuticals Inc. | 1 | $26 |
| Nevro Corp. | 1 | $23 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Sequel Med Tech, LLC | 1 | $15 |
| Cequr Corporation | 1 | $12 |
| Intercept Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$6,764 in reported general payments places this provider in the 75th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
See all endocrinology, diabetes & metabolism providers in Oregon →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 301 | $315,910 |
| JardianceEmpagliflozin | 183 | $146,771 |
| MounjaroTirzepatide | 83 | $106,686 |
| TrulicityDulaglutide | 78 | $106,548 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 55 | $48,802 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $45,083 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $26,877 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $22,546 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 119 | $22,090 |
| FiaspInsulin Aspart (Niacinamide) | 19 | $20,911 |
| FarxigaDapagliflozin Propanediol | 23 | $18,280 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $16,904 |
| HumalogInsulin Lispro | 48 | $16,215 |
| Novolog FlexpenInsulin Aspart | 64 | $13,729 |
| TradjentaLinagliptin | 19 | $11,569 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $732 | $348,208373 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi | $564 | $237,252229 claims |
| Boehringer IngelheimJardiance, Tradjenta | $56 | $158,340202 claims |
| AstraZenecaFarxiga | $583 | $18,28023 claims |
| AbbVieSynthroid | $211 | $11,070143 claims |
| Sanofi-aventis U.S. LLCLantus | $179 | $8,59836 claims |
| MerckJanumet Xr | $143 | $5,88612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
Other endocrinology, diabetes & metabolism in Bend
- Mary CarrollBend$32K
- Mark BurgeBend$909
- Michael McClungPortland$1.3M
- Maria FleseriuPortland$464K
- James NeifingPortland$311K
- Rodica BusuiPortland$255K
- Jonathan PurnellPortland$212K
- Patricia HopsonCorvallis$166K
- Eric OrwollPortland$94K
- Paul DuellPortland$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.